Paper42569746
The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis.
Yeh CN and 1 other. Liver Cancer, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis. Papers, record 42569746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42569746
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20078217 | The senescence-associated secretory phenotype: the dark side of tumor suppression. | Annu Rev Pathol | 2010 | https://conductscience.org/library/papers/20078217 | PubMed |
| 2 | 30136421 | Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma. | Hepatology | 2019 | https://conductscience.org/library/papers/30136421 | PubMed |
| 3 | 35798016 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35798016 | PubMed |
| 4 | 26099527 | Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. | Gastroenterology | 2015 | https://conductscience.org/library/papers/26099527 | PubMed |
| 5 | 11844509 | Laparoscopic living donor hepatectomy for liver transplantation in children. | Lancet | 2002 | https://conductscience.org/library/papers/11844509 | PubMed |
| 6 | 25132496 | ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25132496 | PubMed |
| 7 | 22516259 | Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22516259 | PubMed |
| 8 | 18563841 | Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. | Hepatology | 2008 | https://conductscience.org/library/papers/18563841 | PubMed |
| 9 | 33090190 | The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33090190 | PubMed |
| 10 | 19308066 | Linking DNA methylation and histone modification: patterns and paradigms. | Nat Rev Genet | 2009 | https://conductscience.org/library/papers/19308066 | PubMed |
| 11 | 25747274 | β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25747274 | PubMed |
| 12 | 20951342 | The hippo signaling pathway in development and cancer. | Dev Cell | 2010 | https://conductscience.org/library/papers/20951342 | PubMed |
| 13 | 12395331 | Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. | Hepatology | 2002 | https://conductscience.org/library/papers/12395331 | PubMed |
| 14 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 15 | 30765123 | Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. | Lancet | 2019 | https://conductscience.org/library/papers/30765123 | PubMed |
| 16 | 18552846 | Combinatorial patterns of histone acetylations and methylations in the human genome. | Nat Genet | 2008 | https://conductscience.org/library/papers/18552846 | PubMed |
| 17 | 35325622 | Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35325622 | PubMed |
| 18 | 25294808 | Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. | Oncotarget | 2014 | https://conductscience.org/library/papers/25294808 | PubMed |
| 19 | 35484418 | Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. | Nat Cancer | 2022 | https://conductscience.org/library/papers/35484418 | PubMed |
| 20 | 30287171 | Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30287171 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42569746
GET https://conductscience.org/api/papers/v1/42569746/references?page=2